60 Degrees Pharmaceuticals, Inc.
SXTP
$1.63
-$0.08-4.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 106.84% | 202.12% | 128.69% | 118.37% | 168.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 106.84% | 202.12% | 128.69% | 118.37% | 168.65% |
| Cost of Revenue | -67.42% | -64.50% | -56.11% | 415.31% | 562.36% |
| Gross Profit | 99.19% | 98.01% | 80.67% | -631.33% | -803.70% |
| SG&A Expenses | 24.97% | 25.46% | 17.49% | 24.10% | 18.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.82% | -7.25% | -7.40% | 87.46% | 92.24% |
| Operating Income | 20.14% | 17.16% | 13.94% | -85.41% | -88.47% |
| Income Before Tax | 7.38% | -0.31% | -383.22% | -1,201.98% | -108.61% |
| Income Tax Expenses | -- | 22.22% | 57.14% | -100.00% | -100.00% |
| Earnings from Continuing Operations | 7.38% | -0.32% | -383.14% | -1,201.65% | -108.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -62.79% | -82.90% | -86.13% | -87.01% | -82.12% |
| Net Income | 7.32% | -0.72% | -397.33% | -1,294.74% | -111.03% |
| EBIT | 20.14% | 17.16% | 13.94% | -85.41% | -88.47% |
| EBITDA | 20.58% | 17.56% | 14.28% | -85.86% | -89.35% |
| EPS Basic | 85.32% | 87.46% | -327.82% | -216.55% | -211.26% |
| Normalized Basic EPS | 85.31% | 87.27% | 83.29% | 17.14% | 33.72% |
| EPS Diluted | 85.32% | 87.46% | -327.82% | -216.55% | -211.26% |
| Normalized Diluted EPS | 85.31% | 87.27% | 83.29% | 17.14% | 33.72% |
| Average Basic Shares Outstanding | 488.92% | 671.51% | 652.36% | 724.30% | 872.38% |
| Average Diluted Shares Outstanding | 488.92% | 671.51% | 652.36% | 724.30% | 872.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |